Zobrazeno 1 - 10
of 660
pro vyhledávání: '"rifampicin-resistant"'
Publikováno v:
Public Health Action, Vol 14, Iss 4, Pp 146-151 (2024)
SETTING: Papua New Guinea (PNG) is a high-burden country for multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB). There are limited data on MDR/RR-TB notifications and treatment from the most populous province. OBJECTIVE: Describe MDR/RR-TB de
Externí odkaz:
https://doaj.org/article/d7f29d4f1d4147c39b265cde21e82075
Publikováno v:
Antimicrobial Resistance and Infection Control, Vol 13, Iss 1, Pp 1-12 (2024)
Abstract Background Multidrug- or rifampicin-resistant tuberculosis (TB; MDR/RR-TB) is a significant public health threat. However, the mechanisms involved in its transmission in Sichuan, China are unclear. To provide a scientific basis for MDR/RR-TB
Externí odkaz:
https://doaj.org/article/c09415a66bf84dec95af5b47aed7bfc6
Autor:
Yishak Abraham, Dawit Getachew Assefa, Tesfahunegn Hailemariam, Desye Gebrie, Dejene Tolossa Debela, Simon Tsegaye Geleta, Dagmawit Tesfaye, Michele Joseph, Tsegahun Manyazewal
Publikováno v:
BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-22 (2024)
Abstract Background Drug-resistant tuberculosis (DR-TB) remains a threat to public health. Shorter regimens have been proposed as potentially valuable treatments for multidrug or rifampicin resistant tuberculosis (MDR/RR-TB). We undertook a systemati
Externí odkaz:
https://doaj.org/article/dfb34cffff99493b8d5a0a02c00b116d
Publikováno v:
BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background Rifampicin-resistant pulmonary tuberculosis (RR-PTB) presents a significant threat to global public health security. China bears a substantial burden of RR-PTB cases globally, with Guizhou Province experiencing particularly alarmi
Externí odkaz:
https://doaj.org/article/2f35a7fb2b8d49629eabbaf0edd0d55c
Autor:
Lee-Ann C. Davids, Talitha Crowley
Publikováno v:
Journal of Public Health in Africa, Vol 15, Iss 1, Pp e1-e11 (2024)
Background: Significant strides have been made globally and in South Africa (SA) in the policy and biomedical management of multidrug-resistant tuberculosis (MDR-TB). However, MDR-TB remains a significant public health threat. Aim: This policy conte
Externí odkaz:
https://doaj.org/article/2ae37ca5758d4435ae82fc8ca8c89343
Publikováno v:
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, Vol 37, Iss , Pp 100499- (2024)
Introduction: In Uganda, people with multi-drug resistant and rifampicin-resistant tuberculosis (MDR/RR-TB) have been treated with a bedaquiline-based regimen since 2020. Still, their treatment outcomes have not been rigorously studied. We describe t
Externí odkaz:
https://doaj.org/article/7ada685d242a429085a4e7478f9587a1
Autor:
Lingyun Song, Yilin Zhang, Feng Sun, Yuanbo Lan, Jie Tong, Shijia Ge, Zhen Feng, Rong Li, Hongying Yu, Yang Li, Wenhong Zhang
Publikováno v:
International Journal of Infectious Diseases, Vol 148, Iss , Pp 107230- (2024)
Objectives: Efforts to shorten rifampicin-resistant tuberculosis (RR-TB) treatment have led to concerns about hepatotoxicity in shorter regimens. We evaluated hepatotoxicity in two novel regimens against the standard shorter regimen recommended by th
Externí odkaz:
https://doaj.org/article/9fd96fcc897845d0a1faa23dd54e5dc2
Publikováno v:
Infection and Drug Resistance, Vol Volume 17, Pp 3253-3263 (2024)
Shengling Hu,1– 4 Jinqiang Guo,5 Zhe Chen,6 Fengyun Gong,1– 4 Qi Yu1– 4 1Department of Infectious Diseases, Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430023, People’s Republic of
Externí odkaz:
https://doaj.org/article/55508c270bca4f46974e89e60c9a25f4
Publikováno v:
Infection and Drug Resistance, Vol Volume 17, Pp 1135-1145 (2024)
Hailemariam Mezgebe,1 Teklay Gebrecherkos,2 Dawit Gebreegziabiher Hagos,2 Saravanan Muthupandian3 1Department of Medical Microbiology, College of Health Sciences, Aksum University, Aksum, Tigray, Ethiopia; 2Department of Medical Microbiology and Immu
Externí odkaz:
https://doaj.org/article/35317b4c367848a08010c9002eba41fb
Autor:
Katherine C. McNabb, Alanna J. Bergman, Amita Patil, Kelly Lowensen, Nomusa Mthimkhulu, Chakra Budhathoki, Nancy Perrin, Jason E. Farley
Publikováno v:
BMC Public Health, Vol 24, Iss 1, Pp 1-7 (2024)
Abstract Background Understanding why patients experience loss to follow-up (LTFU) is essential for TB control. This analysis examines the impact of travel distance to RR-TB treatment on LTFU, which has yet to be analyzed within South Africa. Methods
Externí odkaz:
https://doaj.org/article/28512d43004c4fe29b4bbf85ef7a951b